Evotec
Stefano Pizzolato, Ph.D., is an accomplished industrialization senior scientist and process safety specialist currently employed at Evotec since September 2018, with a focus on the transfer and industrialization of synthetic processes for new drug candidates in clinical studies. With expertise in synthetic chemistry gained through various roles including research scientist in medicinal chemistry and senior scientist in molecular discovery, Stefano has substantial experience in route scouting, process optimization, and scale-up of active pharmaceutical ingredients (APIs). Additionally, Stefano has served as an industrial researcher at Edmond Pharma since March 2017, where responsibilities include the synthesis and analysis of APIs, adhering to GMP guidelines. Educational qualifications encompass a PhD in Synthetic Organic Chemistry from the University of Groningen, alongside master's and bachelor's degrees in organic chemistry from Università di Pavia.
This person is not in any teams
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.